The Ratio of GrzB+ - FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma.
Scognamiglio G, Capone M, Sabbatino F, Di Mauro A, Cantile M, Cerrone M, Madonna G, Grimaldi AM, Mallardo D, Palla M, Sarno S, Anniciello AM, Di Bonito M, Ascierto PA, Botti G.
Scognamiglio G, et al. Among authors: botti g.
Cancers (Basel). 2021 May 12;13(10):2325. doi: 10.3390/cancers13102325.
Cancers (Basel). 2021.
PMID: 34066146
Free PMC article.